Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus. Results from the DIGAMI study

European Heart Journal

Volumn 21, Issue 9, 2000, Pages 733-739

  Almbrand, B ^a   Johannesson, M ^b   Sjostrand B ^c   Malmberg, K ^a   Ryden L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^c SBL Vaccin AB   (Sweden)

Author keywords

Cost effectiveness; Diabetes mellitus; Insulin; Myocardial infarction; Survival

Indexed keywords

ANTIDIABETIC AGENT; FIBRINOLYTIC AGENT; GLUCOSE; INSULIN;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG INFUSION; FOLLOW UP; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; INSULIN; MYOCARDIAL INFARCTION; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; VALUE OF LIFE;

EID: 0034083987     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1859     Document Type: Article

References (28)

1. Malmberg K, Rydén L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J. 9:1988;256-264.
2. Stone P, Muller J, Hartwell T. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol. 14:1989;49-57.
3. Karlson BW, Herlitz J, Hjalmarson A. Prognosis of acute myocardial infarction in diabetic and non-diabetic patients. Diabet Med. 10:1993;449-454.
4. Barbash GI, White HD, Modan M, Van dWerff F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 22:1993;707-713.
5. Malmberg K, Rydén L, Efendic S. A randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 26:1995;57-65.
6. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J. 314:1997;1512-1515.
7. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, second edition. 1997;Oxford Medical Publications, Oxford.
8. Johannesson M. Theory and methods of economic evaluation of health care. 1996;Kluwer Academic Publishers, Dordrecht.
9. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 16:1997;33-64.
10. Johannesson M, Meltzer D, O'Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making. 17:1997;382-389.
11. Johannesson M, Meltzer D. Some reflections on cost-effectiveness analysis. Health Economics. 7:1998;1-7.
12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 276:1996;1253-1258.
13. Läkemedelsinformation AB. FASS 1998, Pharmaceutical specialities in Sweden. 1998;Läkemedelsinformation AB, Stockholm.
14. Statistical yearbook of Sweden. 1998;Statistics Sweden, Stockholm.
15. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"): I. Validation of the method. Am J Med. 73:1982;883-888.
16. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"): II. Use in medical decision-making. Am J Med. 73:1982;889-897.
17. Lundberg L, Johannesson M, Isacson DGL, Borgquist L. Health-state utilities in a general population in relation to age, gender, and socioeconomic factors. Eur J Public Health. 9:1999;211-217.
18. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, Lee TH. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 13:1993;161-165.
19. Glasziou PP, Bromwich S, Simes JR. Quality of life six months after myocardial infarction treated with thrombolytic therapy. Med J Australia. 161:1994;532-536.
20. Newbold P. Statistics for business and economics. 1991;Prentice-Hall, Englewood Cliffs.
21. SAMPLAN, Översyn av samhällsekonomiska kalkylvärden för den nationella trafikplaneringen 1994-1998, Stockholm, SAMPLAN, 1995.
22. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 146:1992;473-481.
23. Martens LL, Rutten FF, Erkelens DW, Ascoop CA. Cost-effectiveness of cholesterol-lowering therapy in the Netherlands. Am J Med. 87:1989;54S-58S.
24. Tosteson AN, Rosenthal DI, Melton LJ, Weinstein MC. Cost-effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Int Med. 113:1990;594-603.
25. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 265:1991;1145-1151.
26. van Hout B, Bonsel G, Habbema D, Vandermaas P, Decharro F. Heart transplantation in the Netherlands: costs, effects and scenarios. J Health Econ. 12:1993;73-93.
27. Johannesson M, Borgquist L, Jönsson B, Lindholm LH. The cost effectiveness of lipid lowering in Swedish primary health care. J Intern Med. 240:1996;23-29.
28. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 336:1997;332-336.